PRKN and Parkinson disease: Mitophagy-enhancing therapies designed to increase PINK1 and parkin activity and/or inhibit ubiquitin-specific peptidase 30 (USP30) seem to be a plausible solution to rescue parkin/PINK1 deficiency in Parkinson’s disease caused by PARK2 or PARK6 mutations, as reviewed in Reference [35].